Sarepta Therapeutics (NASDAQ:SRPT) : 12 Wall Street analysts covering Sarepta Therapeutics (NASDAQ:SRPT) believe that the average level the stock could reach for the short term is $21.92. The maximum price target given is $60 and the minimum target for short term is around $4, hence the standard deviation is calculated at $16.39.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Wedbush upgrades its outlook on Sarepta Therapeutics (NASDAQ:SRPT). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Neutral. The brokerage firm raises the price target from $14 per share to $36 per share. The rating by the firm was issued on June 7, 2016.
Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Thursday. Though the stock opened at $17.31, the bulls momentum made the stock top out at $18.1 level for the day. The stock recorded a low of $17.03 and closed the trading day at $17.88, in the green by 2.70%. The total traded volume for the day was 3,404,849. The stock had closed at $17.41 in the previous days trading.
The company shares have dropped -46.69% from its 1 Year high price. On Oct 5, 2015, the shares registered one year high at $41.97 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $18.38 and the 200 Day Moving Average price is recorded at $20.50. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Sarepta Therapeutics, Inc., Behrens M Kathleen had purchased shares worth of $1,165,500 in a transaction dated on March 14, 2016. A total of 75,000 shares were purchased at a price of $15.54 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.